Because the coronavirus pandemic began earlier this yr, the entire world has been patiently ready for the vaccine to supply some kind of immunity to the virus so individuals can return to their regular lives. Now that the vaccines are right here, it looks like issues won’t ever get again to regular. So far, greater than 274,000 Individuals have died from the lethal virus.
Now it seems that there isn’t a assure that the vaccine we’ve got all been ready for can stop the transmission of the coronavirus. In an interview with Dateline host Lester Holt, Pfizer chairman and CEO Albert Bourla mentioned it was not clear whether or not the corporate’s coronavirus vaccine may cease the virus from spreading to different individuals. He mentioned the corporate wasn’t positive anybody may transmit the virus after vaccination. Bourla mentioned:
Pfizer was “unsure” that the vaccine prevented the coronavirus from being transmitted. ”
Bourla added, saying, “That is one thing that must be investigated.” The prime-time particular entitled “Race for a Vaccine” shall be broadcast on Thursday. Holt interviewed Bourla and others who’re concerned within the improvement and distribution of the drug.
In November, Pfizer introduced that its vaccine candidate was proven to be greater than 90 % efficient towards COVID-19 and filed for emergency approval with the Meals and Drug Administration (FDA).
Early final month, Pfizer and its accomplice BioNTech introduced that the COVID-19 vaccine affords 90% safety. After testing the vaccine on 43,500 individuals in 6 international locations, the corporate mentioned the vaccine had no security considerations.
As a part of the interview highlights printed earlier than the particular, Holt Bourla requested: “Despite the fact that I had the safety, can I nonetheless go it on to different individuals?”
“I feel that must be investigated. We’re unsure what we all know proper now, ”Bourla replied.
We wrote about Pfizer again in July after the drug large, and biotech firm BioNTech reportedly improved immune responses in wholesome sufferers. Based on the research, documented in a 16-page article, the researchers randomly chosen 45 sufferers to obtain considered one of three doses of the vaccine or placebo. Twelve acquired a dose of 10 micrograms, 12 acquired a dose of 30 μg, 12 acquired a dose of 100 μg and 9 acquired a placebo. The 100 μg dose triggered fever in half of the sufferers; A second dose was not given at this stage.
Under is a video preview of the interview.
You might be within the best race of our time – the race to make a Covid vaccine. This night, @LesterHoltNBC sits down with the heads of @pfizer, @moderna_tx, and @JNJNews at 10 / 9c on a particular version of #Date limit. pic.twitter.com/sMLX8QEPX2
– Dateline NBC (@DatelineNBC) 3rd December 2020